Healthcare / Medical DevicesNasdaqGS
$0.39
+0.01 (+2.37%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 20%
FCF escenarios
weak_data · normalized FCF $-5.7M · quality 29.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
13/100
F
Piotroski
7/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$46M
P/E
N/A
•EV/EBITDA
7.9x
↓ROE
-2.0%
↓Gross Margin
32.1%
↓Debt/Equity
2.17
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2010–2025 · 15 años de histórico normalizado
Revenue CAGR
+5.0%
FCF CAGR
—
FCF margin
-1.2%
FCF / Net income
3.56x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $458.5M · net income $-1.6M · FCF $-5.7M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||||||||
| Revenue | $458.5M | $458.5M | $446.6M | $447.6M | $429.9M | $396.3M | $382.9M | $418.8M | $404.9M | $383.4M | $398.8M | $379.8M | $369.4M | $316.0M | $409.2M | $222.3M | $221.6M |
| Net Income | $-1.6M | $-1.6M | $-15.5M | $-9.3M | $-5.3M | $-6.3M | $3.8M | $-16.4M | $-23.9M | $-29.6M | $-25.5M | $-40.2M | $-35.4M | $-116.5M | $-78.5M | $-27.1M | $2.8M |
| EBITDA | $20.2M | $20.2M | $5.7M | $8.4M | $11.6M | $28.6M | $20.1M | $11.1M | $5.9M | $8.2M | $13.4M | $324000.00 | $2.4M | $-55.1M | $-23.6M | $-20.3M | $10.0M |
| EPS | -0.02 | -0.02 | -0.16 | -0.10 | -0.06 | -0.07 | 0.04 | -0.19 | -0.28 | — | — | — | — | — | -1.02 | -0.44 | 0.05 |
| Gross Margin | 32.1% | 32.1% | 32.0% | 34.4% | 37.2% | 40.3% | 39.1% | 38.8% | 39.9% | 36.9% | 39.8% | 38.3% | 38.7% | 30.9% | 33.5% | 48.2% | 46.9% |
| Operating Margin | 1.7% | 1.7% | 0.1% | 0.5% | 1.9% | 5.6% | 3.3% | 0.1% | -0.9% | -2.6% | -1.2% | -5.0% | -4.9% | -25.5% | -13.7% | -12.5% | 1.3% |
| Net Margin | -0.3% | -0.3% | -3.5% | -2.1% | -1.2% | -1.6% | 1.0% | -3.9% | -5.9% | -7.7% | -6.4% | -10.6% | -9.6% | -36.9% | -19.2% | -12.2% | 1.3% |
| Balance Sheet | |||||||||||||||||
| Debt/Equity | 2.17 | 2.17 | 4.67 | 3.82 | 3.75 | 2.47 | 2.97 | 3.21 | 2.70 | 1.11 | 2.86 | 2.63 | 1.98 | 1.86 | 0.39 | — | — |
| Current Ratio | 1.42 | 1.42 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Cash Flow | |||||||||||||||||
| Free Cash Flow | $-5.7M | $-5.7M | $-15.5M | $2.9M | $-7.1M | $36.2M | $-5.0M | $-34.0M | $12.1M | $-5.4M | $22.9M | $-24.9M | — | — | — | — | — |
| Returns | |||||||||||||||||
| ROE | -2.0% | -2.0% | -34.5% | -17.3% | -10.1% | -9.2% | 6.0% | -32.9% | -49.1% | -63.6% | -42.7% | -53.1% | -36.0% | -109.1% | -38.5% | -11.3% | — |
| Valuation | |||||||||||||||||
| EV/EBITDA | 7.85 | 7.85 | 54.51 | 55.30 | 24.71 | — | — | — | — | — | — | — | — | — | — | — | — |
| P/B | 0.49 | 0.49 | 3.75 | 6.47 | 3.32 | — | — | — | — | — | — | — | — | — | — | — | — |
| Growth & Yield | |||||||||||||||||
| Revenue Growth | 2.7% | 2.7% | -0.2% | 4.1% | — | 3.5% | -8.6% | 3.4% | 5.6% | -3.9% | 5.0% | 2.8% | 16.9% | -22.8% | 84.1% | 0.3% | — |
| EPS Growth | 87.5% | 87.5% | -60.0% | -66.7% | — | -275.0% | 121.1% | 32.1% | — | — | — | — | — | — | -131.8% | -980.0% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-74.6%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.16 → -0.02
Residual
-74.6%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.